The Georgian Health Digest: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Georgian Health Digest.

October 2025

Mo	Tu	We	Th	Fr	Sa	Su
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

November 2025

Mo	Tu	We	Th	Fr	Sa	Su
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30

December 2025

Mo	Tu	We	Th	Fr	Sa	Su
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

Press releases published on December 8, 2025

December 8, 2025

Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia

GlobeNewswire

December 8, 2025

Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conference

GlobeNewswire

December 8, 2025

Ocular Therapeutix™ Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI™ in Wet AMD

GlobeNewswire

December 8, 2025

Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

GlobeNewswire

December 8, 2025

Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum

GlobeNewswire

December 8, 2025

Monaghan Medical Earns 2025 AARC Zenith Award — A Decade of Trust and Innovation Recognized by Respiratory Care Professionals

GlobeNewswire

December 8, 2025

Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)

GlobeNewswire

December 8, 2025

Sanuwave Announces the Addition of UltraMIST to Healogics Group Purchasing Organization (GPO), iSupply

GlobeNewswire

December 8, 2025

MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND

GlobeNewswire

December 8, 2025

AskForHelpToday.ca Launches in New Brunswick, Improving Access to Mental Health Care

GlobeNewswire

December 8, 2025

AskForHelpToday.ca est lancé au Nouveau-Brunswick, améliorant l’accès aux soins en santé mentale

GlobeNewswire

December 8, 2025

Pan Cancer T Secures EUR 10 Million to Advance First-in-Human Trial of Novel TCR-T Cell Therapy for Triple-Negative Breast Cancer

GlobeNewswire

December 8, 2025

FIRST PATIENT DOSED IN CITRYLL’S PHASE IIA HIDRADENITIS SUPPURATIVA TRIAL

GlobeNewswire

December 8, 2025

EpiEndo Pharmaceutical's ERJ Open Research article reports first clinical trial of glasmacinal (EP395) in COPD patients

GlobeNewswire

December 8, 2025

Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025

GlobeNewswire

December 8, 2025

OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development

GlobeNewswire

$ASH 2025 : Cellectis présente son plan de développement pour renforcer les taux de réponse élevés obtenus avec éti-cel dans le LNH en rechute ou réfractaire$

December 8, 2025

ASH 2025 : Cellectis présente son plan de développement pour renforcer les taux de réponse élevés obtenus avec éti-cel dans le LNH en rechute ou réfractaire

GlobeNewswire

$Miltenyi Biomedicine presenta el análisis primario del ensayo pivotal DALY 2-EU para el linfoma de células B grandes en recaída/refractario de segunda línea en la 67.ª Reunión Anual de la American Society of Hematology (ASH)$

December 8, 2025

Miltenyi Biomedicine presenta el análisis primario del ensayo pivotal DALY 2-EU para el linfoma de células B grandes en recaída/refractario de segunda línea en la 67.ª Reunión Anual de la American Society of Hematology (ASH)

GlobeNewswire

$À l’occasion de la 67e réunion annuelle de l’American Society of Hematology (ASH), Miltenyi Biomedicine présente l’analyse primaire de l’essai pivot DALY 2-EU pour le traitement de seconde ligne du lymphome à grandes cellules B en rechute ou réfractair…$

December 8, 2025

À l’occasion de la 67e réunion annuelle de l’American Society of Hematology (ASH), Miltenyi Biomedicine présente l’analyse primaire de l’essai pivot DALY 2-EU pour le traitement de seconde ligne du lymphome à grandes cellules B en rechute ou réfractair…

GlobeNewswire

December 8, 2025

Miltenyi Biomedicine מציגה ניתוח ראשוני של ניסוי DALY 2-EU מרכזי לטיפול בהישנות/עמידות לטיפול קו שני של לימפומה של תאי B גדולים בכנס השנתי ה-67 של האגודה האמריקנית להמטולוגיה (ASH…

GlobeNewswire